ArticleThe Pan African medical journal2025
Evaluation of the analytical performance of six rapid diagnostic tests for the detection of HIV-1 and 2 in Lubumbashi, Democratic Republic of Congo.
Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human immunodeficiency virus (HIV) infection constitutes a major public health concern worldwide. According to UNAIDS estimates, Africa would be the most affected continent in the world, with around 25.7 million cases recorded, and the Democratic Republic of Congo (DRC) would be among the 22 countries in the world with the heavy burden of HIV. Screening constitutes an important lever in the prevention of this infection. In developing countries such as the DRC, rapid diagnostic tests (RDTs) are widely used in screening for HIV infection. Still, these RDTs might have a serious problem of analytical performance, which could compromise the prevention and medical management of HIV infection. To date, no study has been carried out in Lubumbashi to assess the quality of these RDTs. This study aimed to evaluate the analytical performance of RDTs used in Lubumbashi for the screening and diagnosis of HIV infection. A total of 200 serum samples (100 HIV positive samples and 100 HIV negative samples) were tested simultaneously by six locally used brands of RDTs and by the Liaison XL Murex assay used as a reference test. All six evaluated RDTs showed analytical performance in line with WHO standards, with a sensitivity and NPV of 100%, a specificity and PPV of 99% and a Kappa coefficient of 99%. The Unigold RDT mark, having presented a high detection limit, could be proposed as the RDT of first choice in HIV screening in Lubumbashi.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.